Contribute Try STAT+ Today

An arcane regulatory term known as skinny labeling may have a funny ring to it, but to generic drug makers, it is no laughing matter.

What has the generic industry upset is a recent court ruling that, legal experts say, could effectively negate a key aspect of a decades-old law which makes it possible to supply Americans with many of cheaper generic alternatives to pricey brand-name medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • With the flood, over the last few decades, of judges appointed based on ideological conformity rather than intellectual capacity, I fear it may become increasingly difficult for the federal bench to make sound decisions in complex cases such as this. O tempora, o mores.

Comments are closed.